Invention Grant
- Patent Title: Use of anti-PD-1 antibody in combination with anti-CD27 antibody in cancer treatment
-
Application No.: US15613192Application Date: 2017-06-03
-
Publication No.: US10668152B2Publication Date: 2020-06-02
- Inventor: Vladimir Coric , Tibor Keler , Thomas Davis
- Applicant: Bristol-Myers Squibb Company , Celldex Therapeutics, Inc.
- Applicant Address: US NJ Princeton US NJ Hampton
- Assignee: Bristol-Myers Squibb Company,Celldex Therapeutics, Inc.
- Current Assignee: Bristol-Myers Squibb Company,Celldex Therapeutics, Inc.
- Current Assignee Address: US NJ Princeton US NJ Hampton
- Agency: Sterne, Kessler, Goldstein & Fox P.L.L.C.
- Main IPC: A61K39/395
- IPC: A61K39/395 ; C07K16/28 ; C07K16/30 ; A61K45/06 ; A61K39/00 ; A61P35/00
Abstract:
This disclosure provides methods for treating cancer in a subject comprising administering to the subject an anti-PD-1 antibody and an anti-CD27 antibody. In some embodiments, the cancer is colorectal cancer, rectal cancer, colon cancer, lung cancer, melanoma, ovarian cancer, head and neck cancer, or any combination thereof.
Public/Granted literature
- US20170368172A1 USE OF ANTI-PD-1 ANTIBODY IN COMBINATION WITH ANTI-CD27 ANTIBODY IN CANCER TREATMENT Public/Granted day:2017-12-28
Information query
